Shopping Cart
Remove All
Your shopping cart is currently empty
TLR9-IN-1 (compound 29) is an effective and selective TLR9 inhibitor with an IC50 of 7 nM in human B cells, suitable for autoimmune diseases and inflammation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $329 | - | In Stock |
| Description | TLR9-IN-1 (compound 29) is an effective and selective TLR9 inhibitor with an IC50 of 7 nM in human B cells, suitable for autoimmune diseases and inflammation. |
| Targets&IC50 | HEK/hTLR9:7 nM |
| In vitro | TLR9-IN-1 (0-10 μM, 24 hours) treated human monocytes showed moderate inhibitory activity against IL-1β in cells, with an IC50 of 1.61 μM in human monocytes (co-incubated with TLR8 agonist ORN8L and RNA oligonucleotides). [1] |
| Synonyms | TLR9-IN1 |
| Molecular Weight | 421.54 |
| Formula | C23H31N7O |
| Cas No. | 2226366-86-3 |
| Smiles | O=C(NCCCN(C)C)C1CCN(C2=NN=CC3=CN(N=C32)C4=CC=C(C=C4)C)CC1 |
| Color | Yellow |
| Appearance | Solid |
| Storage | keep away from direct sunlight | store at 4°C | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 420 mg/mL (996.35 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (23.72 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.